Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Kidney disease is a common problem among people with type 1 diabetes and can lead to
disability, dialysis, and early death. Inflammation plays a key role in the development of
kidney disease in type 1 diabetes and targeting leukotrienes, inflammatory chemicals the body
releases in response to allergic reactions, may represent a promising therapy to slow the
progression of diabetic kidney disease. The current proposal will investigate whether
montelukast, a leukotriene blocker, lowers increased levels of protein in the urine (an early
marker of diabetic kidney disease), and improves kidney and cardiovascular function in people
with type 1 diabetes and kidney disease.